CSPC Pharmaceutical Group Limited

Informe acción SEHK:1093

Capitalización de mercado: HK$59.8b

CSPC Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

El CEO de CSPC Pharmaceutical Group es Cuilong Zhang , nombrado en May 2022, tiene una permanencia de 2.5 años. compensación anual total es CN¥13.47M, compuesta por 5.1% salario y 94.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.043% de las acciones de la empresa, por valor de HK$25.65M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 7.7 años, respectivamente.

Información clave

Cuilong Zhang

Chief Executive Officer (CEO)

CN¥13.5m

Compensación total

Porcentaje del salario del CEO5.1%
Permanencia del CEO2.5yrs
Participación del CEO0.04%
Permanencia media de la dirección2.5yrs
Promedio de permanencia en la Junta Directiva7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Nov 15
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Oct 16
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Sep 30
Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20
Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Cuilong Zhang en comparación con los beneficios de CSPC Pharmaceutical Group?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

CN¥5b

Jun 30 2024n/an/a

CN¥6b

Mar 31 2024n/an/a

CN¥6b

Dec 31 2023CN¥13mCN¥693k

CN¥6b

Sep 30 2023n/an/a

CN¥6b

Jun 30 2023n/an/a

CN¥6b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥11mCN¥693k

CN¥6b

Sep 30 2022n/an/a

CN¥6b

Jun 30 2022n/an/a

CN¥6b

Mar 31 2022n/an/a

CN¥6b

Dec 31 2021CN¥9mCN¥693k

CN¥6b

Sep 30 2021n/an/a

CN¥6b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥5b

Dec 31 2020CN¥9mCN¥693k

CN¥5b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥7mCN¥693k

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥3b

Dec 31 2018CN¥4mCN¥298k

CN¥3b

Compensación vs. Mercado: La compensación total de Cuilong($USD1.86M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD735.87K).

Compensación vs. Ingresos: La compensación de Cuilong ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.


CEO

Cuilong Zhang (55 yo)

2.5yrs

Permanencia

CN¥13,472,000

Compensación

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Dongchen Cai
Executive Chairman27.6yrsCN¥26.68m24.16%
HK$ 14.4b
Cuilong Zhang
Vice-Chairman & CEO2.5yrsCN¥13.47m0.043%
HK$ 25.6m
Chunlei Li
Executive Director & Chief Scientist6.9yrsCN¥9.42m0.039%
HK$ 23.1m
Weidong Pan
Executive Directorno dataCN¥4.92m0.013%
HK$ 7.7m
Huaiyu Wang
Executive Directorno dataCN¥5.74m0.013%
HK$ 7.7m
Zhenguo Wang
Executive Directorno dataCN¥4.90m0.013%
HK$ 7.7m
Hao Jiang
Executive Directorno dataCN¥4.02m0.026%
HK$ 15.4m
Xin Cai
Group Executive Presidentno datasin datossin datos
Bing Yao
Executive Directorless than a yearsin datossin datos
Yongjun Liu
Executive president & President of Global Research and Developmentless than a yearsin datossin datos
Tai On Lo
Company Secretary3.8yrssin datossin datos

2.5yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1093 se considera experimentado (2.5 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Dongchen Cai
Executive Chairman27.6yrsCN¥26.68m24.16%
HK$ 14.4b
Cuilong Zhang
Vice-Chairman & CEO6.3yrsCN¥13.47m0.043%
HK$ 25.6m
Chunlei Li
Executive Director & Chief Scientist6.9yrsCN¥9.42m0.039%
HK$ 23.1m
Weidong Pan
Executive Director18.1yrsCN¥4.92m0.013%
HK$ 7.7m
Huaiyu Wang
Executive Director14.1yrsCN¥5.74m0.013%
HK$ 7.7m
Zhenguo Wang
Executive Director12.8yrsCN¥4.90m0.013%
HK$ 7.7m
Hao Jiang
Executive Director4yrsCN¥4.02m0.026%
HK$ 15.4m
Xin Cai
Group Executive Presidentless than a yearsin datossin datos
Bing Yao
Executive Directorless than a yearsin datossin datos
Chun Kwok Au
Independent Non-Executive Director3.8yrsCN¥340.00ksin datos
Bo Wang
Independent Non-Executive Director11.9yrsCN¥142.00ksin datos
Chuan Chen
Independent Non-Executive Director8.4yrsCN¥142.00ksin datos

7.7yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1093 se considera experimentada (7.7 años de antigüedad promedio).